“The Center for Intelligent Imaging will serve as a hub for the multidisciplinary development of AI in imaging to meet unmet clinical needs and provide a platform to measure impact and outcomes of this technology,” said Christopher Hess, MD, PhD, chair of the UCSF Department of Radiology and Biomedical Imaging.

More than 50% of the 43.7 million foreign-born people living in the U.S. are female—that figure is only expected to grow, explained lead author Tainya Clarke, PhD, MPH.

“I am honored and excited to be named the editor of the RSNA Case Collection, a key initiative to create a comprehensive online resource of clinical cases for the practicing radiologists,” said its new editor, Mariam Moshiri, MD.

There is no shortage of research investigating the effectiveness of the Breast Imaging Reporting and Data System (BI-RADS) category 3 in mammography, but what’s less understood is why some women complete follow-up recommendations while many do not.

New research utilizing functional MRI (fMRI) has cast doubts on a commonly believed theory about dyslexia, potentially paving the way for new approaches to the learning disorder.

GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.

The voluntary standards—"EMA/MITA HN 1-2019, Manufacturer Disclosure Statement for Medical Device Security,” or MDS2—include a standardized form for manufacturers to complete with detailed information on the security features embedded in medical devices.

A group of U.S. researchers analyzed literature on the topic, summarizing imaging findings to help radiologists identify signs of vaping-related lung injuries. The results were published Oct. 8 in the American Journal of Roentgenology.

A newly created four-dimensional virtual catheter technique allows for reproducible, automated estimation of blood flow in patients with congenital bicuspid aortic valve (BAV), reported authors of an Oct. 8 study published in Radiology.

The funds, managed by Oaktree Capital Management, will support SHINE’s commercialization of molybdenum-99 and lutetium-177 (Lu-177) in addition to construction of the physical production facility.